Scorching COVID-19 Era Returns From India Biotech, Healthcare Funds Outpace The Globe
Indian E-pharmacies, Online Consulting Firms Raise Over $740m
Executive Summary
Early COVID-19 therapies including Gilead’s remdesivir, China-plus procurement policies, vaccine partnerships and a dovish stance by the central bank led to returns on India biotech and healthcare funds outperforming global returns. Meanwhile, funding for e-pharmacies and online consulting firms gathered pace.
You may also be interested in...
APAC Podcast: Policies Play Out Against Pandemic, Corporate Activity Remains Strong
Join the Asia Pacific content team for a wide-ranging overview and analysis of recent developments across China, India, South Korea and Japan in the policy, regulatory, commercial and vaccines spaces over the past few months.
APAC Podcast: Policies Play Out Against Pandemic, Corporate Activity Remains Strong
Join the Asia Pacific content team for a wide-ranging overview and analysis of recent developments across China, India, South Korea and Japan in the policy, regulatory, commercial and vaccines spaces over the past few months.
In Pfizer, J&J’s Innovation Centers, Incubators Lie Paths To Indian Innovation
Executives from J&J, Pfizer and Johns Hopkins share ideas on driving Indian biopharma innovation via innovation centers and incubators set up in association with academic institutions. On the other side of the table, Indian academia highlights the need for industry participation in skill building and the perils of ‘targeted thinking’